Neurodevelopmental Institute of New Hampshire (NINH) Announces Partnership with NEBA Health LLC: Offering NEBA Brainwave-based ADHD Test
Augusta, GA (October 29, 2020) – NEBA® Health, LLC announced Neurodevelopmental Institute of New Hampshire (NINH) is now a NEBA partner in Hooksett, NH offering the only FDA cleared brainwave- based ADHD assessment aid.
About Clinic and About Clinician
Originally designed to diagnose and treat children with neurodevelopmental disorders, NINH evolved into an agency that serves people across the lifespan. NINH has expanded services throughout the entire state and is committed to helping each individual reach their potential through a holistic approach to diagnosis and treatment.
Dr. Susan McLaughlin-Beltz is the President and serves as the neuropsychologist for NINH with certifications in EEG Biofeedback, Critical Incident Stress Management, Sensory Integration and Praxis Testing, Special Education, NAPPI, Fast ForWord, IMPACT, SAFE Home Study, Certified Clinical Trauma Professional and Trust-Based Relational Intervention (TBRI®) Practitioner. She is currently trained in Eye Movement Desensitization and Reprocessing Therapy (EMDR) and a fellow at the Academy for Integrative Health and Medicine.
NEBA is a 15 to 20-minute test that integrates an EEG biomarker for ADHD into the clinical setting. Using NEBA, clinicians can significantly reduce the number of patients receiving ADHD treatment and management as the initial focus when another condition would potentially be the primary diagnosis. In the FDA validation study, NEBA reduced the potential for over-diagnosis from 34% to 3%. NEBA also provides confirmatory support for ADHD with an accuracy of 92%. Clinicians conduct their evaluation as in their regular practice using their usual assessment tools. NEBA uses EEG to separate ADHD patients into biomarker-based groups with clinical differences that allow validated recommendations to be offered to the clinicians.
Dr. Steve Snyder, Vice President of Research and Development said “NEBA can help the clinician to confirm ADHD as primary diagnosis and can help the clinician to determine whether ADHD-like symptoms may be better explained by another primary condition. “A clinician using NEBA is more likely to converge upon diagnostic evaluation results of a multidisciplinary team.
About NEBA Health
NEBA® Health develops diagnostic tools to help clinicians improve the lives of children and families. We developed the first FDA cleared Neuropsychiatric Interpretative Electroencephalograph Assessment Aid (NIEA) — named NEBA®. We have a variety of programs including NEBA-Cares to provide need-based assistance. We have ongoing work in ADHD, depression, and dementia. NEBA is an ISO 13485 registered medical device developer. We are cleared for marketing in the USA as (K112711), CE marked, and Health Canada licensed.
Dr. Susan McLaughlin-Beltz (603)621-9870
FRM0058/2020.05.11 NEBA Health LLC Content Only